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Genome-wide association studies (GWAS) have identified 
ten loci harboring common variants that influence risk of 
developing colorectal cancer (CRC). To enhance the power to 
identify additional CRC risk loci, we conducted a meta-analysis 
of three GWAS from the UK which included a total of 3,334 
affected individuals (cases) and 4,628 controls followed by 
multiple validation analyses including a total of 18,095 cases 
and 20,197 controls. We identified associations at four new 
CRC risk loci: 1q41 (rs6691170, odds ratio (OR) = 1.06,  
P = 9.55 × 10−10 and rs6687758, OR = 1.09, P = 2.27 × 10−9), 
3q26.2 (rs10936599, OR = 0.93, P = 3.39 × 10−8), 12q13.13 
(rs11169552, OR = 0.92, P = 1.89 × 10−10 and rs7136702, OR =  
1.06, P = 4.02 × 10−8) and 20q13.33 (rs4925386, OR = 0.93, 
P = 1.89 × 10−10). In addition to identifying new CRC risk loci, 
this analysis provides evidence that additional CRC-associated 
variants of similar effect size remain to be discovered.
GWAS of CRC have confirmed the hypothesis that part of the herit-
able risk for this disease is caused by common, low-risk variants1. Our 
previous analyses, based on two GWAS from the UK (UK1, also known 
as CORGI) and Scotland (Scotland1, also known as COGS), identified 
ten common variants associated with CRC risk2. These variants map to 
8q24.21 (rs6983267), 8q23.3 (rs16892766, EIF3H), 10p14 (rs10795668), 
11q23 (rs3802842), 14q22.2 (rs4444235, BMP4), 15q13 (rs4779584), 
16q22.1 (rs9929218, CDH1), 18q21.1 (rs4939827, SMAD7), 19q13.1 
(rs10411210, RHPN2) and 20p12.3 (rs961253).
The discovered effect sizes of the individual associations and the need 
for stringent thresholds for establishing statistical significance inevitably 
constrain the power of individual GWAS to detect common variants. To 
augment our ability to detect additional CRC loci, we undertook a further 
GWAS analysis of a set of cases from the VICTOR and QUASAR2 clini-
cal trials of adjuvant therapy in potentially curable colorectal carcinoma. 
These trials recruited cases from throughout the UK. The controls were 
from the UK population-based 1958 Birth Cohort, for which genotype 
data are publicly available. Together, this case-control set (henceforth 
referred to as VQ58) comprised 1,432 cases and 2,697 controls.
The VQ58 cases were genotyped in house using the Illumina Hap300 
and Hap370 SNP arrays. After filtering both the VQ data and the 
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 publicly available control data to remove SNPs and individuals that fell 
below pre-determined quality control standards (Online Methods), we 
examined associations between genotype and CRC status. A quantile-
quantile plot showed no evidence of systematic inflation of the allelic 
test statistic (genomic control inflation factor (λgc) = 1.018). No indi-
vidual SNP showed association with CRC under dominant, additive 
or recessive models at genome-wide significance (set at P ≤ 1.0 × 10−7 
based on a Bonferroni correction). This was not unexpected given the 
power of the VQ58 dataset to detect associations of the magnitudes 
found in our previous analyses of the UK and Scottish GWAS2. We 
therefore proceeded directly to a combined analysis of UK1 (CORGI) 
and Scotland1 (COGS) and VQ58 (Supplementary Table 1). Quality 
control measures were standardized throughout the sample sets. We 
used principal components analysis (PCA) to examine whether there 
was evidence of distinct genetic subgroups within the three GWAS. 
After removal of 88 outliers and 6 duplicate samples, the Scottish and 
UK (UK1 (CORGI) and VQ58) samples essentially clustered together, 
with minor variation in the first component reflecting the known 
north-west to south-east cline in the UK (Supplementary Fig. 1).
The UK1 and Scotland1 samples had previously been genotyped 
using Illumina Hap550 arrays. We therefore imputed genotype prob-
abilities in the VICTOR and QUASAR2 samples at SNPs not present 
on the Illumina Hap300 and Hap370 arrays. Of the SNPs we imputed, 
94,867 out of 214,649 passed our threshold of ≤5% missing genotypes 
and an information score of ≥0.5. We then conducted a meta-analysis 
of the three datasets (Supplementary Table 1) using the Mantel-
Haenszel method under both fixed- and random-effects models. 
Only one SNP (rs4939827 on chromosome (chr.) 18q21.1), which 
was previously shown to be associated with CRC risk3–5, achieved 
genome-wide significance for association.
At this stage, we considered whether to include data we had gen-
erated from two additional large UK case-control sets in our meta-
analysis: UK2 (NSCCG) (comprising 2,854 cases and 2,822 controls) 
and Scotland2 (SOCCS) (comprising 2,024 cases and 2,092 controls) 
(Supplementary Table 1). These additional samples had been geno-
typed at 55,000 SNPs with the strongest evidence of association from 
a meta-analysis of the UK1 (CORGI) and Scotland1 (COGS) GWAS2. 
If we were to include these extra data, essentially we had to weigh two 
factors: (i) the extra power afforded by including UK2 (NSCCG) and 
Scotland2 (SOCCS) data compared to (ii) the probability that a true 
CRC SNP had not been taken forward into the top 55,000 SNPs from 
the UK1 and Scotland1 meta-analysis but did make it into a smaller 
set of top SNPs in a VQ58, UK1 and Scotland1 meta-analysis. Power 
calculations showed that, except for rare alleles with small effects for 
which the power of detection was in any event low, the extra power 
provided by the UK2 and Scotland2 samples more than compen-
sated for the loss of a few true disease-associated SNPs that would 
not have reached the significance threshold for genotyping in UK2 
and Scotland2 (Supplementary Fig. 2).
We therefore undertook a meta-analysis of VQ58, UK1 (CORGI), 
Scotland1 (COGS), UK2 (NSCCG) and Scotland2 (SOCCS) (Fig. 1). 
Seven SNPs achieved significant associations (P < 10−7) in this analysis. 
All these SNPs had previously been shown to be associated with CRC 
risk. After exclusion of SNPs in strong pairwise linkage disequilib-
rium (LD) (r2 > 0.7), we selected seven SNPs (rs11805285, rs6687758, 
rs6691170, rs10936599, rs7136702, rs11169552 and rs4925386) with 
nominal associations at P < 5.0 × 10−5. All of these SNPs had been 
genotyped, rather than imputed, in the VQ dataset. These seven SNPs 
underwent validation testing in 9,883 CRC cases and 10,655 controls 
from six independent, northern European case-control series (COIN 
(NBS), Helsinki, UK3 (NSCCG), UK4 (CORGI2BCD), Scotland3 
(SOCCS) and Cambridge; Supplementary Table 1). This threshold for 
follow up did not exclude the possibility that other SNPs represented 
genuine association signals, but was simply a pragmatic strategy for 
prioritizing replication. After further genotyping, significant associa-
tions were confirmed for six SNPs mapping to four loci: rs6687758 
(P = 2.27 × 10−9) and rs6691170 (P = 9.55 × 10−10) at 1q41; rs10936599 
(P = 3.39 × 10−8) at 3q36.2, rs7136702 (P = 4.02 × 10−8) and rs11169552 
(P = 1.89 × 10−10) at 12q13.13; and rs4925386 (P = 1.89 × 10−10) at 
20q13.3 (Fig. 2, Table 1 and Supplementary Table 2). There was no 
significant between-study heterogeneity for these SNP associations 
(Phet > 0.05 for all SNPs; Table 1), and no SNP showed any evidence 
of association with age or sex in any dataset (P > 0.05).
rs6691170 (on chr. 1 at location 220,112,069) and rs6687758 (on 
chr. 1 at 220,231,571) lie 125 kb from each other on chromosome 1q41 
(Table 1). The region containing these two SNPs (Fig. 3) is flanked by 
recombination hotspots close to rs3003888 (on chr. 1 at 220,049,548) 
and rs6687797 (on chr. 1 at 220,296,043). Between these sites, LD rela-
tionships are complex and LD blocks are not easily defined, although a 
minor recombination hotspot exists on chr. 1 at 220,137,516 between 
rs6691170 and rs66867758. rs6691170 and rs66867758, respectively, 
lie 250 kb and 125 kb upstream of DUSP10, which encodes a dual-
 specificity phosphatase that inactivates p38 and SAPK (JNK). The 
region otherwise contains few genes but does contain several spliced 
ESTs. In the UK datasets, rs6691170 and rs6687758 were in modest 
pairwise LD (r2 = 0.22 and D′ = 0.71), raising the possibility that these 
SNPs may represent independent signals of association. We assessed 
this using multiple logistic regression analysis stratified by sample 
series in which genotypes at one SNP were assessed conditional on 
Series 1: VQ58
1,432 stage 2 and 3 CRC cases
2,697 population controls
Series 2: UK1 (CORGI)
922 familial CRC and CRAd cases
929 unaffected spouse controls
Series 3: Scotland1 (COGS)
980 early onset CRC cases
1,002 population controls
Series 4: UK2 (NSCCG)
2,854 CRC cases
2,822 unaffected controls
Series 5: Scotland2 (SOCCS)
2,024 CRC cases
2,092 population controls
Validation Series
9,973 CRC cases and 10,655 controls from
COIN (NBS), UK3 (NSCCG), UK4 (CORGI2BCD),
Scotland3 (SOCCS), Helsinki, Cambridge
6 SNPs validated
Hap550 data
Hap300 and Hap370 data
Combined Hap550 and
custom 50K array data.
15 SNPs with P < 10–4.
Select 7 SNPs with 
P < 5 × 10–5
Figure 1 Overall study design.
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those at the other SNP. We found that rs6691170 had an OR of 1.07 
(P = 6.15 × 10−5), and rs6687758 had an OR of 1.06 (P = 1.92 × 
10−4). Individuals with the high-risk haplotype (TG) at rs6691170 and 
rs6687758 had a 1.15-fold increased risk of CRC compared to those 
individuals with the low-risk haplotype (GA) (P = 5.39 × 10−8).
rs10936599 (on chr. 3 at 170,974,795) is flanked by recombination 
hotspots at chr. 3 position 170,837,364 and chr. 3 position 171,082,143 
(Fig. 3). rs10936599 lies at 3q26.2 within MYNN (the myoneurin 
gene), which encodes a zinc finger protein of unknown function that 
is expressed principally in muscle. rs10936599 is also close to the 
actin-related protein M1 locus.
rs7136702 (on chr. 12 at 49,166,483) and rs11169552 (on chr. 12 at 
49,441,930) lie about 275 kb apart within what is essentially a large, 
poorly-defined haplotype block (Fig. 3) composed of a set of smaller 
blocks but with considerable long-range LD between markers (chr. 12 
spanning 48,658,293–49,505,968). rs7136702 is just telomeric to the 
myeloproliferative oncogene binding-protein gene LARP4 and 30 kb 
proximal to DIP2 (encoding disco-interacting protein 2B), which may 
have a role in determining epithelial cell fate. rs11169552 is just telo-
meric to DIP2B and proximal to ATF1 (encoding activating transcrip-
tion factor 1). ATF1 is the 3′ partner in the recurrent translocations 
with EWSR1 (22q12) that contribute to the development of soft-tissue 
clear-cell sarcomas6. rs7136702 and rs11169552 map close to a known 
chromosomal fragile site, but we found that colorectal tumors rarely 
show somatic chromosomal breakpoints at this site7. rs7136702 and 
rs11169552 are not strongly correlated (r2 = 0.11 and D′ = 0.76 in 
the UK samples). We therefore tested independence of these signals 
using conditioned logistic regression analysis just as we did for the 
chromosome 1 signals. In this combined analysis, the rs11169552 
signal nearly retained global significance (OR = 0.91, P = 4.33 × 10−7), 
whereas the strength of association at rs7136702 was reduced (OR = 
1.06, P = 4.34 × 10−4). Individuals with the high-risk haplotype (TC) 
at rs7136702 and rs11169552 had a 1.14-fold increased risk of CRC 
compared with the low-risk haplotype (CT) (P = 6.90 × 10−8).
rs4925386 (on chr. 20 at 60,354,439) is within a very small haplo-
type block (on chr. 20 spanning 60,330,882–60,355,038), although 
table 1 Summary results for six SNPs associated with colorectal cancer
SNP Locus
Discovery
P
Replication
P
Overall
POR (95% CI) OR (95% CI) OR (95% CI)
rs6691170 1q41 1.06 (1.03–1.09) 3.05 × 10−5 1.06 (1.03–1.09) 6.48 × 10−6 1.06 (1.03–1.09) 9.55 × 10−10
rs6687758 1q41 1.10 (1.06–1.15) 2.73 × 10−6 1.08 (1.04–1.12) 1.57 × 10−4 1.09 (1.06–1.12) 2.27 × 10−9
rs10936599 3q26.2 0.91 (0.88–0.95) 2.03 × 10−6 0.95 (0.91–0.98) 1.87 × 10−3 0.93 (0.91–0.96) 3.39 × 10−8
rs7136702 12q13.13 1.06 (1.03–1.09) 1.19 × 10−5 1.05 (1.02–1.08) 6.50 × 10−4 1.06 (1.04–1.08) 4.02 × 10−8
rs11169552 12q13.3 0.92 (0.89–0.96) 1.24 × 10−5 0.93 (0.90–0.96) 3.66 × 10−6 0.92 (0.90–0.95) 1.89 × 10−10
rs4925386 20q13.33 0.93 (0.90–0.96) 6.80 × 10−6 0.93 (0.91–0.96) 6.48 × 10−6 0.93 (0.91–0.95) 1.89 × 10−10
Odds ratios (95% CIs) and P values from the allelic test are shown for the discovery phase, the replication phase and overall for each of the six SNPs associated with risk of CRC. 
Further details are provided in Supplementary table 2.
rs6687758 rs6691170 rs10936599
rs11169552 rs7136702 rs4925386
Series
VQ58
Series
0.8 0.9 1.0 1.12 1.25 0.8 0.9 1.0 1.12 1.25 0.8 0.9 1.0 1.12 1.25
VQ58
Series
VQ58
Series
VQ58
Series
VQ58
Series
VQ58
UK1 (CORGI)
Scotland1 (COGS)
UK2 (NSCCG)
Scotland2 (SOCCS)
COIN (NBS)
UK3 (NSCCG)
UK4 (CORGI2BCD)
Scotland3 (SOCCS)
Helsinki
Cambridge
UK1 (CORGI)
Scotland1 (COGS)
UK2 (NSCCG)
Scotland2 (SOCCS)
COIN (NBS)
UK3 (NSCCG)
UK4 (CORGI2BCD)
Scotland3 (SOCCS)
Helsinki
Cambridge
UK1 (CORGI)
Scotland1 (COGS)
UK2 (NSCCG)
Scotland2 (SOCCS)
COIN (NBS)
UK3 (NSCCG)
UK4 (CORGI2BCD)
Scotland3 (SOCCS)
Helsinki
Cambridge
UK1 (CORGI)
Scotland1 (COGS)
UK2 (NSCCG)
Scotland2 (SOCCS)
COIN (NBS)
UK3 (NSCCG)
UK4 (CORGI2BCD)
Scotland3 (SOCCS)
Helsinki
Cambridge
UK1 (CORGI)
Scotland1 (COGS)
UK2 (NSCCG)
Scotland2 (SOCCS)
COIN (NBS)
UK3 (NSCCG)
UK4 (CORGI2BCD)
Scotland3 (SOCCS)
Helsinki
Cambridge
UK1 (CORGI)
Scotland1 (COGS)
UK2 (NSCCG)
Scotland2 (SOCCS)
COIN (NBS)
UK3 (NSCCG)
UK4 (CORGI2BCD)
Scotland3 (SOCCS)
Helsinki
Cambridge
Figure 2 Forest plots of effect size and direction for the six SNPs associated with CRC. Boxes denote allelic OR point estimates with their areas being 
proportional to the inverse variance weight of the estimate. Horizontal lines represent 95% CIs. The diamond (and broken line) represents the summary 
OR computed under a fixed effects model, with the 95% CI indicated by its width. The unbroken vertical line is at the null value (OR = 1.0).
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it shows moderate LD with distal mark-
ers outside the block (Fig. 3). rs4925386 
lies within LAMA5 (encoding large lam-
inin A5), which is required for the produc-
tion of noggin, a secreted BMP antagonist. 
It is notable that other BMP pathway SNPs 
are likely to be involved in CRC predispo-
sition2. rs4935386 is in moderate to strong 
LD (r2 > 0.5) with four non-synonymous 
LAMA5 SNPs which lead to the substitutions 
p.Ala1908Thr, p.Arg2226His, p.Asp2062Asn 
and p.Val1900Met, although all of these 
alterations are predicted to be benign.
For both 1q41 and 12q13.12, the two signals, if independent, might 
have resulted from two causal variants or from a single causal vari-
ant strongly associated with disease and correlated with both SNPs 
in the region. For each region, we addressed the latter possibil-
ity by imputing SNPs from the HapMap2 European CEU samples 
between the flanking recombination hotspots. We conducted logistic 
regression analysis of the GWAS and UK2 (NSCCG) and Scotland2 
(SOCCS) datasets, conditioning on the genotypes at each of the two 
identified SNPs. Although a small number of imputed SNPs from 
12q13.12 had a stronger predicted association than the genotyped 
SNPs (Supplementary Fig. 3), no single imputed SNP was able to 
account for the dual signals in either the 1q41 or 12q13.12 region.
To explore whether any of these newly discovered CRC associations 
resulted from cis-acting regulatory elements, we examined whether 
any of the six SNPs tagged reported expression quantitative trait loci 
(eQTLs) for nearby genes. Although four SNPs had no association 
with known eQTLs, rs7136702 was in moderate to strong LD (r2 = 0.47 
to r2 = 0.61 and D′ = 0.80 to D′ = 0.84) with four SNPs (rs11169520, 
rs11169524, rs3742062 and rs2280503) that have previously been 
associated with DIP2B expression in lymphoblastoid cell lines8. 
Furthermore, rs492536 was in moderate to strong LD (r2 = 0.61, D′ = 
0.78) with rs13043313, an eQTL for LAMA5 expression in the liver7.
Using a case-only design, we searched for pairwise gene-gene inter-
actions between the six new CRC susceptibility SNPs and also between 
these six SNPs and the ten previously identified risk SNPs (rs6983267, 
rs16892766, rs10795668, rs3802842, rs4444235, rs4779584, rs9929218, 
rs4939827, rs10411210 and rs961253)2. Although there was suggestive 
evidence of epistasis between rs6687758 and rs7136702 (P = 7.70 × 
10−4), this evidence did not meet the threshold for significance after 
adjustment for 120 comparisons (P = 4.2 × 10−4). There was no evi-
dence to suggest any functional relationships between genes close to 
these SNPs. No other evidence of gene-gene interactions was found 
(data not shown).
We identified four new CRC risk loci, none of which maps to 
previously reported cancer predisposition genes of high or low 
penetrance. At two of these loci, there exists the possibility that 
two SNPs independently predict risk. Our study illustrates other 
general issues that currently affect large-scale studies to identify 
common predisposition alleles. Allelic ORs were less than 1.10 for 
each of the CRC SNPs we identified. Power to detect the effects of 
such loci was therefore modest, with the likelihood of discovery 
being highly sensitive to small chance differences in genotype fre-
quencies, especially in the three GWAS datasets. Therefore, many 
more CRC loci of similar effect size may exist. Although the new 
CRC risk alleles we have identified collectively account for ~1.5% 
of the familial CRC risk, in concert with other alleles they have the 
potential to substantially influence disease risk and thus have an 
application to risk stratification at a population level. Finally, the 
loci we identified are likely to provide fresh insights into the etio-
logical basis of CRC.
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Figure 3 Regional plots. (a–d) Maps of the 1q41 (a), 
3q26.2 (b), 12q13.13 (c) and 20q13.33 (d) 
regions showing evidence of association with CRC 
and local LD structure. In the association plot, 
each point represents a SNP genotyped at this 
locus. For each SNP at the position (kb) shown 
on the x axis, −log10 P from the allelic association 
test is indicated on the y axis. The recombination 
rate is shown in blue. The SNP with the strongest 
association in each region is shown as a red 
diamond. Data were derived from the combined 
analysis of the VQ58, UK1, Scotland1, UK2 and 
Scotland2 cohorts, which resulted in relatively 
few SNPs being shown for each region but which 
illustrates the rationale for the selection of SNPs 
for genotyping in the validation sample sets. In 
the LD plots (lower), derived from HapMap CEU 
individuals in Haploview, the color intensity of 
each SNP represents the strength of LD according 
to the standard Haploview scheme for r2 (with 
black indicating values >0.90 through shades 
of gray to white, which indicate a value of 0.0). 
Physical positions are based on NCBI build 36 of 
the human genome.
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URLs. Detailed information on the tag SNP panel, http://
www.illumina.com/; Haploview, http://www.broadinstitute.
org/haploview/haploview; VICTOR and QUASAR2, http://
www.octo-oxford.org.uk/; PLINK, http://pngu.mgh.harvard.
edu/~purcell/plink/; dbSNP, http://www.ncbi.nlm.nih.gov/
entrez/query.fcgi?CMD=search&DB=snp; HapMap, http://www.
hapmap.org/; Kbioscience, http://kbioscience.co.uk/; STATA, 
http://www.stata.com/; GELCAPS, http://pfsearch.ukcrn.org.
uk/StudyDetail.aspx?TopicID=1&StudyID=781; National Study 
of Colorectal Cancer Genetics (NSCCG), http://pfsearch.ukcrn.
org.uk/StudyDetail.aspx?TopicID=1&StudyID=1269; 1958 
Birth Cohort, http://www.b58cgene.sgul.ac.uk/; WTCCC2, 
http://www.wtccc.org.uk/ccc2/wtccc2_studies.shtml; Genetic 
Power Calculator, http://pngu.mgh.harvard.edu/~purcell/gpc/; 
IMPUTE v2, https://mathgen.stats.ox.ac.uk/impute/impute_
v2.html; Eigenstrat, http://genepath.med.harvard.edu/~reich/
Software.htm; SNAP, http://www.broadinstitute.org/mpg/snap; 
PolyPhen, http://genetics.bwh.harvard.edu/pph/.
MeThOdS
Methods and any associated references are available in the online 
 version of the paper at http://www.nature.com/naturegenetics/.
Note: Supplementary information is available on the Nature Genetics website.
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ONLINe MeThOdS
Study participants. A summary of all cases and controls in the study is 
provided in Supplementary Table 1. After exclusion of self-reported non-
white UK cases and samples of poor quality, VQ58 comprised 1,432 CRC 
cases (896 males with a mean age of diagnosis of 62.4 years ± 10.7 (standard 
deviation)) from the VICTOR and QUASAR2 trials. There were 2,697 popula-
tion control genotypes (1,391 male) from the Wellcome Trust Case Control 
Consortium 2 (WTCCC2) 1958 birth cohort9 (also known as the National 
Child Development Study), which included all births in England, Wales and 
Scotland during a single week in 1958.
The compositions of the UK1 (CORGI), Scotland1 (COGS), UK2 (NSCCG), 
Scotland2 (SOCCS), UK3 (NSCCG), Scotland3 (SOCCS), Helsinki and 
Cambridge sample sets have been described previously10 and are described 
in the Supplementary Note. The COIN samples comprised 2,151 cases (1,423 
males) derived from the COIN and COIN-B clinical trials of metastatic CRC 
with a median age of 63 years (range, 22–87 years). COIN cases were com-
pared against genotypes from 2,501 population controls (1,237 males) from 
the WTCCC2 National Blood Service (NBS) cohort. The UK4 (CORGI2BCD) 
samples comprised additional CRC cases and unaffected spouse or partner 
controls from the CORGI study collected in the time since collection of the 
UK1 (CORGI) samples. In all cases, CRC was defined according to the ninth 
revision of the International Classification of Diseases (ICD) by codes 153-154, 
and all cases had pathologically proven disease.
Collection of blood samples and clinico-pathological information from 
cases and controls was undertaken with informed consent and ethical review 
board approval in accordance with the tenets of the Declaration of Helsinki.
Genotyping. DNA was extracted from samples using conventional methods 
and quantified using PicoGreen (Invitrogen). The VQ, UK1 and Scotland 1 
GWAS cohorts were genotyped using Illumina Hap300, Hap370, Hap240S or 
Hap550 arrays. The genotyping of the 1958 Birth Cohort and NBS cohort was 
performed as part of the WTCCC2 study. In the UK2 (NSCCG) and Scotland2 
(SOCCS) samples, genotyping was conducted using custom Illumina Infinium 
arrays according to the manufacturer’s protocols. To ensure the quality of the 
genotyping, a series of duplicate samples was genotyped, which resulted in 
99.9% concordant calls.
Other genotyping was conducted using competitive allele-specific PCR 
KASPar chemistry (KBiosciences Ltd). Genotyping quality control was tested 
using duplicate DNA samples within studies and SNP assays together with 
direct sequencing of subsets of samples to confirm genotyping accuracy. For 
all SNPs, >99.9% concordant results were obtained.
Quality control. We excluded SNPs from analysis if they failed one or more of 
the following thresholds: GenCall score <0.25; overall call rate <95%; minor 
allele frequency <0.01; departure from Hardy-Weinberg equilibrium in con-
trols at P < 10−4 or in cases at P < 10−6; outlying in terms of signal intensity or 
X:Y ratio; discordance between duplicate samples; and, for SNPs with evidence 
of association, poor clustering on inspection of X:Y plots.
We excluded individuals from analysis if they failed one or more of the 
following thresholds: duplication or cryptic relatedness to the estimated 
identity-by-descent (IBD) >6.25%; overall successfully genotyped SNPs 
<95%; mismatch between predicted and reported gender; outliers in a plot of 
heterozygosity versus missingness; and evidence of non-northern European 
ancestry by PCA-based analysis in comparison with HapMap samples. In 
addition, PCA was used to exclude individuals or groups distinct from the 
main cluster using the first three principal components, initially based on 
separate analysis of the VQ58, UK1 and Scotland1 cohorts (as well as the NBS 
cohort) and subsequently based on combined analysis of all three datasets 
(Supplementary Fig. 1). To identify individuals who might have non-northern 
European ancestry, we merged our case and control data with the 60 European 
(CEU), 60 Nigerian (YRI) and 90 Japanese (JPT) and 90 Han Chinese (CHB) 
individuals from the International HapMap Project. For each pair of individu-
als, we calculated genome-wide identity-by-state distances based on markers 
shared between HapMap2 and our SNP panel and used these as dissimilarity 
measures upon which to perform PCA. The first two principal components 
for each individual were plotted, and any individual not present in the main 
CEU cluster (that is, having >5% of the principal component distance from the 
HapMap CEU cluster centroid) was excluded from subsequent analyses.
The adequacy of the case-control matching and the possibility of differential 
genotyping of cases and controls was formally evaluated using quantile-quantile 
plots of test statistics. The inflation factor (λ) was calculated by dividing the 
mean of the lower 90% of the test statistics by the mean of the lower 90% of 
the expected values from a χ2 distribution with 1 degree of freedom (d.f.). 
Deviation of the genotype frequencies in the controls from those expected 
under Hardy-Weinberg equilibrium was assessed by a χ2 test with 1 d.f. or a 
Fisher’s exact test where an expected cell count was greater than five.
Association between SNP genotype and disease status was primarily 
assessed in PLINK v1.07 using allelic and Cochran-Armitage tests (both with 
1 d.f.) or by a Fisher’s exact test where an expected cell count was greater 
than five. Genotypic (2 d.f.), dominant (1 d.f.) and recessive (1 d.f.) tests were 
also performed. The risks associated with each SNP were estimated by allelic, 
heterozygous and homozygous ORs using unconditional logistic regression, 
and associated 95% CIs were calculated.
Joint analysis of data generated from multiple phases was conducted using 
standard methods for combining raw data based on the Mantel-Haenszel 
method in STATA and PLINK. The reported meta-analysis statistics were 
derived from an analysis of allele frequencies, and joint ORs and 95% CIs 
were calculated assuming fixed- and random-effects models. Tests of the sig-
nificance of the pooled effect sizes were calculated using a standard normal 
distribution. The Cochran’s Q statistic to test for heterogeneity11 and the I2 
statistic12 to quantify the proportion of the total variation due to heterogeneity 
were calculated. Large heterogeneity is typically defined as I2 ≥ 75%. Where 
significant heterogeneity was identified, results from the random-effects 
model were reported. We also performed a meta-analysis based on allele dos-
age (0, 1 or 2) and incorporated age and sex as covariates. Although age and 
sex are associated with colorectal cancer risk, they were not associated with 
SNP genotype and did not materially affect the significance of any of the six 
reported associations (data not shown).
We used Haploview software v4.2 to infer the LD structure of the genome in 
the regions containing loci associated with disease risk. The combined effects of 
pairs of loci identified as associated with CRC risk were investigated by multiple 
logistic regression analysis in PLINK to test for independent effects of each SNP 
and stratifying by sample series. Evidence for interactive effects between SNPs 
(epistasis) was assessed by a likelihood ratio test assuming an allelic model in 
PLINK. The ORs for increasing numbers of deleterious alleles were estimated 
by counting two for a homozygote and one for a heterozygote at each of the 16 
risk SNPs, and a trend test was performed on the resulting data.
The sibling relative risk attributable to a given SNP was calculated using 
the following formula:
l* ( ) ( )
( )
= + + +
+ +
p pr qr q pr q
p r pqr q
2 1
2
1
2
2
2 1
2 22
where p is the population frequency of the minor allele, q = 1 – p, and r1 and r2 
are the relative risks (estimated as OR) for heterozygotes and rare homozygotes 
relative to common homozygotes13. Assuming a multiplicative interaction, 
the proportion of the familial risk attributable to a SNP was calculated as 
log(λ*) / log(λ0), where λ0 is the overall familial relative risk estimated from 
epidemiological studies of CRC, which was assumed to be 2.2 (ref. 14). The 
UK2 (NSCCG2) samples were used for this estimation.
Imputation from HapMap2 build 36 was performed using the IMPUTE2 
program (see URLs), incorporating the Hap550-typed UK controls from the 
UK1 (CORGI) study as a reference panel for the VQ58 Hap300 panel geno-
types. SNPs were included in the analysis if there were ≤5% missing genotypes 
and an information score ≥0.5. SNPtest was used to perform the association 
meta-analysis. PCA was performed using Eigenstrat using CEU, YRI and HCB 
HapMap samples as references.
Genome coordinates were taken from the NCBI build 36/hg18 (dbSNP b126).
9. Power, C., Jefferis, B.J., Manor, O. & Hertzman, C. The influence of birth weight 
and socioeconomic position on cognitive development: does the early home and 
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